Results and expectations

retatrutide results timeline

Published May 3, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

Trial timelines are measured over weeks and months. Fast anecdotal changes should not be treated as a personal forecast.

Direct answer

Retatrutide clinical results are reported at study endpoints such as 24, 40, 48, and 68 weeks depending on the trial. Some people expect immediate appetite or scale changes, but the evidence base is built around structured trial timelines and medical monitoring.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quotesubstantial reductions in body weight

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

The obesity trial supports research-result context, but the findings are trial data, not personal expectations or dosing guidance.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quoterandomized, double-blind, placebo-controlled trial

Sanyal et al., Nature Medicine 2024 retatrutide MASLD phase 2a trial

The MASLD substudy adds peer-reviewed evidence for metabolic research context, but it is still not public-use approval.

Short source quoteObesity is a chronic disease

Jastreboff et al., NEJM 2022 SURMOUNT-1 tirzepatide obesity trial

This tirzepatide trial is useful comparison context, but tirzepatide labels and prescriber review still govern real treatment decisions.

Short source quoteObesity is a global health challenge

Wilding et al., NEJM 2021 STEP 1 semaglutide obesity trial

This semaglutide trial provides approved-GLP-1 context for comparison and alternatives pages, not retatrutide dosing guidance.

What to know before acting on this search

Lilly's phase 2 obesity data reported weight outcomes at 24 and 48 weeks.
Lilly's TRANSCEND-T2D-1 topline results reported A1C and weight outcomes at 40 weeks.
Lilly's TRIUMPH-4 topline results reported outcomes at 68 weeks in adults with obesity or overweight and knee osteoarthritis.
Scale changes early in weight loss can include water, glycogen, digestive-content, inflammation, and calorie-intake shifts.

Safety and compliance notes

Rapid weight loss can raise concerns about dehydration, gallbladder symptoms, under-eating, and lean-mass loss.
A slow first month does not prove a product is fake, and a fast first month does not prove a product is safe.
Photos and personal stories can motivate users, but they should not replace approved labels or clinician oversight.

Safer next step

Pair expectations with clinical-trial context, side-effect monitoring, and a clinician-reviewed weight-management plan.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.